Skip to main content

Table 2 Cross-resistance of HMECd1 and HMECd2

From: Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy

 

IC50 μg/ml (RI)

HMEC-1

HMECd1

HMECd2

Doxorubicin

0.0028 ± 0.0003 (1)

0.1 ± 0.027 (35.7) *

0.5 ± 0.01 (178.5) *

Daunorubicin

0.018 ± 0.009 (1)

0.92 ± 0.01 (51.1) *

1.7 ± 0.78 (94.4) *

Vinblastine

0.023 ± 0.007 (1)

0.16 ± 0.03 (69.5) *

0.2 ± 0.03 (86.9) *

Etoposide

0.0031 ± 0.0006 (1)

0.062 ± 0.0062 (20) *

0.6 ± 0.094 (203.5) *

Mytomycin C

0.16 ± 0.0074 (1)

0.15 ± 0.071 (0.9)

0.18 ± 0.0003 (1.1)

  1. The cells were cultured for 72 hours at 37°C in the presence of increasing concentrations of Dox, Etoposide, Daunorubicin, Mytomycin C, or Vinblastine, then incubated with 1 μCi 3H-thymidine/well for 1 hour at 37°C. The radioactivity incorporated into the cell was then measured. IC50 were determined over three separate experiments. Results are expressed as the mean ± SEM. *p <0.05 for statistical significance.